

ORDER

New Delhi, the 26th March, 2024

S.O. 1550(E).—In implementation of directions of review orders issued by the Department of Pharmaceuticals (DOP) under para 31 of Drugs (Prices Control) Order, 2013 vide order(s) specified in column (8) of the table below and in exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 9(a) & 9(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes/revises the prices as specified in column (6) and further revised the prices w. e. f. 01.04.2024 specified in column (7) of the table herein below as ceiling prices exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.	Medicines	Dosage form & Strength	Unit	Ceiling Price under NLEM, 2022 (Rs.)	Revised ceiling price as per review order (in Rs.)	Ceiling price (wef 1.4.2024 with WPI @ 0.00551%) (in Rs.)	Review Order number and date	Existing SO number and date	
								9(a)	9(b)
(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)		
1.	Cefuroxime	Oral liquid 125mg/5mL(p)	1 ML	5.28	5.31	5.31	31015/21/2023 -Pricing dated 08.02.2024	1574 (E)	31-03-23
2.	Montelukast	Tablet 5 mg (including chewable Tablet s)	1 Tablet	11.72	12.01	12.01	31015/12/2023 -Pricing dated 19.02.2024	4663 (E)	25-10-23
3.	Mycophenolate mofetil	Tablet 500mg	1 Tablet	73.88	74.59	74.59	31015/13/2023 -Pricing dated 22.02.2024	4663 (E)	25-10-23

Notes: -

- All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled formulations at price higher than the ceiling price (plus Goods and Services Taxes as applicable) as fixed and notified by the Government as specified in column (6) of the above table, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (6) plus Goods and Services Taxes as applicable, if any.
- All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price as specified in column (6) in the above table (plus Goods and Services Taxes as applicable, if any) shall continue to maintain the existing MRP in accordance with para 13(2) of DPCO,2013 till 31.03.2024.
- The ceiling prices as specified in column (7) of the table are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). All the existing manufacturers of above-mentioned scheduled formulations having MRP lower or equal than the ceiling price as specified in column (6), as on 31.03.2024, in the above table (plus Goods and Services Taxes as applicable, if any) may revise the MRP on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013.
- The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (6) and/or (7) of the above said table.
- Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging.

- (f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (6) and/or (7) applicable of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (i) The manufacturers of above said scheduled formulations shall furnish quarterly return to NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (k) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

[PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II]

YUVIKA PANWAR, Assistant Director

आदेश

का. आ. 1551(अ).—राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण, औषध विभाग, रसायन एवं उर्वरक मंत्रालय द्वारा कोरोनारी स्टेंट्स के अधिकतम मूल्य निर्धारण के संबंध में जारी अधिसूचनाओं का.आ. 639(अ) दिनांक 12.02.2018, 1464(अ) दिनांक 02.04.2018, 1488(अ) दिनांक 29.03.2019, 1217(अ) दिनांक 25.03.2020, 1334(अ) दिनांक 25.03.2021, 1502(अ) दिनांक 30.03.2022, 5249(अ) दिनांक 11.11.2022, 1572(अ) दिनांक 31.03.2023 और 1502(अ) दिनांक 25.10.2023 जारी में उस सारणी के स्तंभ (4) में विनिर्दिष्ट अधिकतम कीमत के संबंध में यह निर्णय लिया गया है कि वर्ष 2022 की अपेक्षा वर्ष 2023 के लिए @ 0.00551% की दर से थोक मूल्य सूचकांक (डब्ल्यूपीआई) पर विचार करने के बाद एतद्वारा कोरोनारी स्टेंट्स के वर्णित अधिकतम मूल्यों, वस्तु एवं सेवा कर, यदि कोई है, को छोड़कर, इस सारणी के स्तंभ (4) में विनिर्दिष्ट अधिकतम कीमत, स्तंभ (3) में वर्णित इकाई के मददेनजर दिनांक 01.04.2024 से निम्न प्रकार से संशोधित किया जाता है:

सारणी

क. सं.	(कोरोनरी स्टेंट्स) (डीपीसीओ, 2013 की अनुसूची-I में क.सं.28)	इकाई (संख्या में)	अधिकतम कीमत (थोक मूल्य सूचकांक सहित 0.00551% की दर से 01.04.2024 से प्रभावी (रुपये में)
(1)	(2)	(3)	(4)
1	सादे धातु स्टेंट	1	10509.79
2	औषध क्षालन स्टेंट (डीईएस) जिसमें धात्विक डीईएस और जैव अवशोष्य वाहिका ढांचा (बीवीएस)/जैव अवकमणीय स्टेंट सम्मिलित हैं।	1	38267.18